The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
A 20-year-old in Italy struggled to get a finasteride prescription from multiple dermatologists due to concerns about side effects and age, despite using minoxidil. Eventually, they obtained a prescription from a hair transplant surgeon.
Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The post and conversation are about hair loss treatments that have been found to be effective in studies. There are 19 different treatments mentioned, including oral minoxidil, oral dutasteride, topical finasteride, RU58841, and more. The best treatment for an individual depends on factors like availability, cost, side effects, and personal preferences.
The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.
Hair loss impacts mental health and should be covered by healthcare, with treatments like finasteride, dutasteride, and minoxidil being affordable and effective. Some argue hair loss is cosmetic and shouldn't be funded, while others highlight its broader health implications.
A user is concerned about the legitimacy of their finasteride from Simple Online Pharmacy. Another user notes similarities and differences with their own order from Dr. Fox but is unsure about the authenticity.
A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.
A 22-year-old was advised by their doctor to use 5% minoxidil for hair loss instead of finasteride due to age and potential side effects. Other users suggested either persisting with the doctor or finding a new one, sharing mixed experiences with finasteride.
The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.
The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.
The conversation discusses the legitimacy of purchasing Pyrilutamide (KX-826) for hair loss treatment. Users mention using Minoxidil and express interest in waiting for phase 3 trials for safety and efficacy confirmation.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
A 31-year-old man chose minoxidil over finasteride due to concerns about erectile dysfunction. He intends to seek another doctor's opinion on finasteride.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
A user preparing to start finasteride for hair loss wanted to check for any abnormal bloodwork related to hair loss. They shared their blood test results and learned from another user that their doctor prescribed finasteride without any preliminary tests.
Facing fears and making a doctor appointment to get more info on individual hair loss cases, as well as the discussion of potential treatments such as Finasteride/Dutasteride, Minoxidil, or RU58841.